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MSL: Mean sleep latency 
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 We evaluated factors associated with subjective and objective sleepiness at baseline and after 
6 months of continuous positive airway pressure (CPAP) therapy in patients with obstructive 
sleep apnea (OSA).  
We analyzed data from the Apnea Positive Pressure Long-term Efficacy Study (APPLES), a 
prospective 6-month multicenter randomized controlled trial with 1105 subjects with OSA, 558 of 
who were randomized to active CPAP. Epworth sleepiness scores (ESS) and the mean sleep 
latency (MSL) on the maintenance of wakefulness test at baseline and after 6 months of CPAP 
therapy were recorded. 
Excessive sleepiness (ESS > 10) was present in 543 (49.1%) participants. Younger age, 
presence of depression and higher apnea-hypopnea index (AHI) were associated with higher 
ESS scores and lower MSL. Randomization to the CPAP group was associated with lower odds 
of sleepiness at 6-months. The prevalence of sleepiness was significantly lower in those using 
CPAP >4hours /night versus using CPAP ≤4 hours a night. Among those with good CPAP 
adherence, those with ESS >10 at baseline had significantly higher odds (OR 8.2, P<0.001) of 
persistent subjective sleepiness. 
Lower average nightly CPAP use and presence of sleepiness at baseline were independently 
associated with excessive subjective and objective sleepiness after 6 months of CPAP therapy.   
  
Excessive daytime sleepiness (EDS) is frequently reported in patients with obstructive sleep 
apnea (OSA). Conversely, OSA has been suggested to be the most common medical disorder 
that causes EDS. 1 A variety of factors may be associated with EDS in OSA patients. Several 
studies have assessed the association between the apnea-hypopnea index (AHI) and 
sleepiness, but while some studies found an association between AHI and EDS, 2-5 others did 
not.6-8 Obesity, oxygen desaturation index and depressive symptoms have also been associated 
with EDS in OSA patients. 9-11 However, many of these studies had small sample sizes or did 
not have objective means of assessment such as the multiple sleep latency test (MSLT) or 
maintenance of wakefulness test (MWT). Furthermore, while several medical and psychiatric 
disorders have been associated with poor sleep quality and insomnia,12-14 there are few 
investigations assessing the impact of comorbid disorders on sleepiness in OSA.  Finally, there 
are few large studies assessing the factors associated with residual sleepiness in patients on 
CPAP therapy.   
The Apnea Positive Pressure Long-term Efficacy Study (APPLES) was a prospective 
multicenter randomized controlled trial designed to assess the impact of CPAP on several 
domains of neurocognitive outcomes in adults with OSA. Participants with OSA were 
randomized to either active CPAP or sham CPAP for 6 months. The subjects completed a 
number of questionnaires including the Epworth sleepiness scale (ESS) and underwent several 
tests including the MWT at baseline and 6 months after initiation of CPAP therapy.  
In this report, we evaluated the prevalence of subjective and objective sleepiness as well as 
demographic and polysomnographic variables and medical and psychiatric conditions 
associated with sleepiness in participants with OSA. We also assessed the factors associated 
with sleepiness after 6-months of CPAP therapy. Specifically, we aimed to evaluate the impact 
of different levels of CPAP adherence on prevalence of sleepiness.  
METHODS: 
Study Design 
The APPLES protocol has been described in detail elsewhere.15 In brief, participants were 
recruited from sleep clinics and through public advertisements at 5 sites: Stanford University, 
Stanford, CA; University of Arizona, Tucson, AZ; Providence St. Mary Medical Center, Walla 
Walla, WA; St. Luke’s Hospital, Chesterfield, MO; and Brigham and Women’s Hospital, Boston, 
MA. Those who did not have exclusion criteria during the initial interview and consented to 
participate in the study underwent a diagnostic polysomnogram (PSG). Those who had an AHI ≥	
10/h without severe oxygen desaturation (i.e., oxygen saturation < 75% for > 10% of the 
diagnostic sleep study) were randomized to either active or sham CPAP (REMStar Pro, Phillips 
Respironics, Murrysville, PA) for 6 months.  The participants randomized to active CPAP then 
underwent a titration in the sleep laboratory to determine the optimal therapeutic pressure. A 
sham titration was performed for those randomized to sham CPAP. Although participants’	
adherence was monitored continuously during the study, for this report we calculated adherence 
at the 6-month time point after initiation of CPAP.  
Participants 
Of the 1516 participants screened, 1105 were ultimately randomized [268 participants 
removed from study pre-randomization due to exclusion criteria (e.g., taking exclusionary 
medication); 143 participants withdrew study “pre-randomization” for any reason (e.g., too 
busy)],15 with 558 assigned to active CPAP and 547 assigned to sham CPAP. Heated 
humidification was used in all participants. Staff (e.g., respiratory therapists, sleep technologists, 
physicians) worked in a systematic manner to troubleshoot nasal congestion and other problems 
that may have been reported by a participant. Subjects using hypnotics, anxiolytics, sedating 
antidepressants, anticonvulsants, sedating antihistamines, stimulants, or other medications likely 
to affect neurocognitive function and/or alertness were excluded from the study. Some subjects 
were on antidepressants and some on opioids, including that in antitussive medications. 
Pre-existing Medical Conditions: 
At their baseline visit, all participants underwent a clinical evaluation including a physical 
examination to obtain a medical history and information pertaining to symptoms of sleep 
disorders, and presence of other medical and psychiatric conditions such as cardiovascular 
disease (CVD), gastroesophageal reflux disease (GERD), chronic pain, nasal congestion and 
depression. A condition was considered present when the participant answered that they currently 
had it. Furthermore, the Hamilton Rating Scale for Depression (HAMD)16 was administered at 
baseline and at the 6-month post-CPAP follow-up visit. We considered a score ≥ 8 as indicative 
of depression being present.  
Epworth Sleepiness Scale (ESS)17,18 
The ESS is one of the most widely used assessments of subjective daytime sleepiness. It is a 
self-administered questionnaire where individuals rate their usual chances of dozing off or falling 
asleep in 8 common situations or activities on a 4-point scale (0 – 3). Hence, the minimum 
possible score on the scale is 0 (not sleepy at all) and the maximum is 24 (extremely sleepy). 
The ESS was administered at baseline and at 6 months after starting	active CPAP or sham 
CPAP.  Sleepiness was considered clinically significant if the ESS total score was > 10.  
Maintenance of Wakefulness Test (MWT)18,19 
The MWT test is used to assess objective daytime sleepiness. With the participant sitting in bed 
with eyes	open, it measures sleepiness when the intent is to stay awake. Hence, it provides an 
objective estimate of the propensity to fall asleep when people would want to stay awake during 
their normal day. The MWT was performed at baseline and at the	2- and 6-month follow-up 
visits. For this study, we used the tests performed at the baseline and 6-month follow-up visits.  
Briefly, after overnight PSG (diagnostic at baseline and with patient’s own CPAP at 6 months), 
four 20-min trials were conducted at 10:00 AM, 12:00 noon, 2:00 PM, and 4:00 PM. A trial was 
ended after 20 minutes or after 3 consecutive 30-second epochs of any stage of sleep, 
whichever occurred first. Once a trial was terminated, the room lights were turned on and the 
subject was asked to open his or her eyes, stay seated in bed, and remain awake until the 20 
min of the trial had elapsed. The mean sleep latency (MSL) of all 4 trials was used for these 
analyses. Interrater reliability assessments were conducted for PSGs and MWTs blindly scored 
by the Data Coordinating Center PSG Technologists, and the Data Coordinating Center was 
responsible for further quality assurance/quality control procedures for these data.15 
CPAP Adherence 
Adherence to active CPAP or sham CPAP was measured objectively using Encore Pro 
SmartCards (Phillips Respironics, Inc., Murrysville, PA) that were exchanged at the clinic twice 
monthly. For this report, at the 6-month period after start of CPAP, the mean hours of daily use 
were analyzed for the preceding 2-month period to assess adherence during that time interval. 
The Smart Card is a memory card that records data regarding the duration of each CPAP therapy 
use and provides reliable objective evidence of CPAP use. 
Statistical Analyses 
To assess the factors associated with sleepiness at baseline, we included all 1105 participants. 
For the 6-month analyses, we focused only on those randomized to active CPAP therapy with 
relevant data available. For assessment of residual sleepiness in those with good adherence, 
analyses were limited to those participants who were using CPAP >4 hours a night. For 
continuous variables, unadjusted comparisons between groups were made using Student’s 
unpaired t-test. Data were expressed as mean ±	SD. Differences in proportions were assessed 
using the χ2 test. Logistic regression was used to assess odds ratios (with 95% confidence 
intervals) for sleepiness (ESS >10) at baseline and at 6 months after CPAP initiation, with 
predictors of interest including demographic and polysomnographic characteristics and comorbid 
conditions. A multiple regression model was used to examine the association between the ESS 
scores and MSL values as dependent variables, with demographic and polysomnographic 
characteristics and comorbid conditions at baseline and at 6 months.  The statistical significance 
level was set at P<0.05 (2-tailed) for all tests. Statistical analyses were conducted using SPSS v	
20.0 for Windows (SSPS Inc, Chicago, IL). 
 
 
RESULTS 
Sleepiness at baseline 
A total of 1105 participants were assessed, including 382 women and 723 men, of whom 611 
(55%) had severe OSA defined as AHI >30.  The baseline demographics for all participants and 
subsequently randomized participants stratified by gender are provided in an earlier 
publication.20 Briefly, the mean age of the participants was 51.5 (12.2), mean BMI was 32.2 
(7.1) mean AHI was 38.2 (26.7) and the mean Oxygen Desaturation Index was 25.5 (25.1). The 
mean baseline ESS of the participants was 10.4±4.4 (minimum 0, maximum 22). In bivariate 
analyses, women were significantly sleepier (ESS 10.9±4.5 vs. 10.2±4.3, P=0.006) than men. 
There was a trend for severe sleep apnea to be sleepier than those without severe sleep apnea 
(ESS 10.7±4.5 vs. 10.2±4.3, P=0.07). The ESS scores correlated directly with BMI, several 
polysomnographic variables including AHI, and HAMD score, and inversely with age (Table 1). 
Of the 1105 participants, 543 (49.1%) had excessive sleepiness (ESS > 10). As shown in Table 
2, the ESS total scores as well as proportion of participants who were sleepy (ESS > 10) were 
higher in those with depression and chronic pain. Except for a trend towards greater sleepiness 
in those with GERD, no differences were observed in a variety of other medical and psychiatric 
conditions. Of all subjects, 196 were on antidepressants and 73 were on opiates. The use of 
antidepressants (P=0.31) or opiates (P=0.15) was not significantly associated with greater 
sleepiness. 
 
A linear regression model revealed younger age, higher AHI and elevated HAMD scores to be 
independently associated with higher ESS total scores (Table 3a). Logistic regression showed 
higher odds of sleepiness in those with depression (HAMD scores ≥8, OR=1.4, P=0.03) and 
lower odds with increasing age (Table 3b).  
 The MWT MSL at baseline (MSL-B, n=1086) was 17.0 minutes (minimum 1.9 minutes, 
maximum 20 minutes). An MSL-B equal to 20 minutes was seen in 521 participants (48%) and 
an MSL-B <20 minutes in 565 participants (52%). For these analyses, a MSL <20 minutes was 
considered abnormal. Notably, we repeated analyses using MSL ≤17 minutes as abnormal, 
which was seen in 37.5% (n=407) of all participants at baseline. The results obtained using this 
cutoff to define sleepiness were generally similar to those obtained using MSL <20 minutes as 
abnormal. 
As expected, MSL-B was significantly lower in those with ESS >10 than those with ESS ≤10 
(16.3±4.3 minutes vs. 17.7±3.5 minutes, P<0.001). Of those with ESS >10, 61.2% had a MSL-B 
<20 minutes compared to only 43.2% in those with ESS ≤10 (P<0.001). Logistic regression 
showed that younger age, presence of depression and AHI >30 were associated with higher 
odds of sleepiness (MSL-B <20 minutes) (Table 3c). 
 
Sleepiness at 6 months after CPAP initiation 
The mean age of the participants randomized to CPAP was 52.2 ± 12.1 years, mean BMI was 
32.3 ± 7.4, mean AHI was 39.5 ± 24.9 and the mean Oxygen Desaturation Index was 26.3 ± 
24.1. At 6-month period, the mean AHI in this group was 6.1 ± 8.3 and the mean Oxygen 
Desaturation Index was 4.8 ±7.3. In contrast, the mean AHI in the sham group at 6 months was 
29.8 ± 25.1 and the mean Oxygen Desaturation Index was 24.8 ±24.9. The ESS was 
significantly lower in the CPAP group compared to the sham group at 2-month (7.9 vs. 8.8, 
P=0.003), 4-	month (7.0 vs. 8.2, P<0.001) and 6- month (7.3 vs. 8.4, P=0.003) periods after 
initiation of therapy despite similar ESS at baseline (10.5 vs. 10.5, P=0.99).  
 At 6 months, 88 (22.3%) of the 394 participants initiated on CPAP had excessive sleepiness 
defined as ESS >10. The mean nightly adherence at 6 months in those randomized to active 
CPAP was 4.70 ± 2.04 hours and 67.3% of the participants were using CPAP > 4 h per night. 
Further details of adherence in the study participants are provided in an earlier publication.21 
The prevalence of sleepiness generally declined progressively with increasing CPAP use 
(Figure 1). The prevalence of sleepiness was higher in those using CPAP ≤4 hours/night versus 
those using CPAP >4hours a night (31% vs. 18%, P=0.003). Fewer hours of CPAP use and 
higher ESS total scores at baseline were independently associated with higher 6-month ESS 
total scores in a linear regression model (Table 4a). A logistic regression model (Table 4b) 
showed lower odds of sleepiness in those using CPAP >4 hours a night (OR=0.42, P=0.001), 
and higher odds in those who were sleepy at baseline (OR=5.1, P<0.001). Women had lower 
odds of sleepiness than men, the presence of chronic pain was associated with higher odds and 
the presence of depression was associated with a trend towards higher odds of sleepiness 
(Table 4b).  The use of antidepressants (n=100, P=0.4) or opiates (n=38, P=0.08) was not 
significantly associated with ESS >10. 
 
The MWT and CPAP adherence data were available for 380 participants randomized to CPAP, 
6-months after initiation of therapy. The mean sleep latency on MWT at 6–months (MSL-6m) 
was 18 minutes. MSL-6m was significantly higher in those using CPAP >4hours a night 
compared to those using CPAP 4 hours or less (18.5±2.8 vs. 17.5±3.8 minutes, P=0.01). MSL-
6m was <20 minutes in 147 participants (38.7%) and ≤17 minutes in 90 participants (23.7%). 
Logistic regression revealed significantly lower odds of excessive sleepiness, defined as MSL-
6m <20 minutes (MSL-6m <20), in those using CPAP >4 hours a night (OR=0.55, P=0.008).  
Those with MSL-B <20 minutes also had significantly higher odds of MSL-6m <20 (OR=6.7, 
P<0.001) (Table 4c). Using a cutoff of 17 minutes for MSL-6m to define sleepiness yielded 
similar results.  
Sleepiness at 6 months in participants with good adherence to CPAP 
The prevalence of ESS >10 was 18.1% (48/265) among those using CPAP >4 hours a night. 
The presence of excessive sleepiness at 6 months in these patients with good CPAP adherence 
was higher in those with baseline excessive sleepiness, whether assessed by ESS >10 (OR 
8.2, P<0.001) or MSL-B <20 minutes (OR=9.6, P<0.001). No other variables assessed, 
including age, BMI, AHI on the sleep study done at 6-months, presence of depression, chronic 
pain or GERD, were significantly associated with odds of sleepiness at 6 months in this group of 
patients.   
Discussion 
The current study found that excessive sleepiness, as measured by ESS total score >10 or a 
MSL <20 minutes on MWT, was present in half the patients with sleep apnea, and was 
associated with presence of depression, more severe sleep apnea and younger age. The 
prevalence of excessive sleepiness 6 months after initiating CPAP was greatly reduced to 
22.3%, and was inversely associated with mean hours of CPAP use. Presence of excessive 
sleepiness at baseline was a strong determinant of excessive sleepiness after 6 months of 
therapy, even in those who had good adherence to CPAP.  
We found that younger age, higher AHI and presence of depression are associated with 
increased sleepiness in patients with sleep apnea. The past literature assessing association 
between AHI and EDS has shown conflicting results, with some studies 2-5 but not others6-8 
showing an association. The studies that have not shown this association probably reflect a 
referral bias, since sleepy patients are more likely to be referred for sleep evaluation, thereby 
obscuring the relation of AHI to sleepiness that is seen in population-based studies. 
The association between depression and increased sleepiness confirms findings of prior reports 
10,22,23.  Depression is a common finding in patients with OSA. We found an 18.6% prevalence of 
depression, defined as HAMD score ≥8. This is similar to a 20.8% prevalence of depression 
found in patients with untreated OSA in a recent study. 22 Similar to that study, we found an 
association between depression and ESS. This strongly argues for making appropriate inquiries 
for the presence of depression in those with SDB, especially in presence of sleepiness.  
The ESS scores and prevalence of sleepiness decreased with increasing age, as has been 
reported in some prior studies. 23,24 This may be related to less potent sleep homeostasis 
mechanisms with increasing age, including morphological and neurological changes in 
suprachiasmatic nucleus and a reduction in melatonin concentration with aging.25  These 
findings suggest that complaints of sleepiness in the elderly would represent a less common 
response, and should not be considered a normal part of the physiologic aging process.  
Lower average nightly CPAP use and presence of sleepiness at baseline were the primary 
determinants of residual sleepiness identified in this study. The effect of good adherence on 
reducing sleepiness confirms the benefit of this therapy demonstrated in the past studies.26-28 
We found, however, that after 6 months of CPAP therapy, 22.3% of the participants on CPAP 
(18.1% of those using CPAP >4 hours a night) still had sleepiness.  This prevalence is close to 
that noted in recent studies,27,28 and is similar to the prevalence of excessive sleepiness in the 
general population among those without sleep apnea.4 Thus, while increasing CPAP adherence 
beyond 4 hours per night might yield some further reduction in daytime sleepiness, much of the 
residual sleepiness in these patents may be caused by factors other than OSA, indicating the 
importance of evaluating patients with residual sleepiness on CPAP for alternative causes of 
sleepiness.  Oxidative injury to sleep-wake brain regions from long-term intermittent hypoxia has 
been suggested as a reason for residual sleepiness following treatment of OSA.29 However, 
reasons for sleepiness, such as chronic pain or other conditions contributing to repeated 
wakefulness at night, sedative medications, depression, poor sleep hygiene or insufficient 
habitual sleep duration should be sought and modified before attributing residual sleepiness to a 
failure of CPAP therapy.  In view of the finding that those who were sleepy at baseline had 
significantly higher odds (OR 8.2, P<0.001) of sleepiness despite good CPAP adherence, it is 
imperative that these patients be closely followed to ensure improvement in sleepiness.   
The study has several limitations. First, we used the ESS for assessment of sleepiness in 
patients with OSA. The ESS, while a commonly used measure of sleepiness, has only a limited 
correlation with objective sleepiness measurements.30 However, we also used the MWT, an 
objective measurement of ability to resist sleep onset, and the results were similar to those 
obtained using subjective measurements from the ESS. Second, while we used MWT-SL to 
objectively assess ability to maintain wakefulness, the optimal MWT cutoff values in those with 
OSA have not been defined. To overcome this limitation, we used different cutoff values to 
decide whether the patients had decreased wakefulness. Notably, we obtained similar 
predictors of sleepiness while using these different cutoffs, and the results were consistent with 
those obtained using ESS. Third, the information about medical and psychiatric conditions was 
self-reported in most cases and obtained only at baseline. Hence, whether the conditions were 
present at the 6-month evaluation period, and may have influenced sleepiness, is not clear.  
Furthermore, apart from depression, for which we had HAMD scale values, the severity of other 
conditions was not assessed. Fourth, residual confounding by several factors including habitual 
sleep duration, disorders not documented in the study, medications, and genetic and 
socioeconomic factors cannot be excluded.31 Finally, the standard MWT administration consists 
of 40-minute nap opportunities, while the naps in this trial were only 20 minutes. However, the 
resultant ceiling effect is expected to reduce power to detect effects of treatment and makes the 
differences with therapy even more compelling.  
In conclusion, this study shows that depression, younger age and higher AHI, are associated with 
sleepiness in people with OSA. CPAP use is associated with reduced odds of sleepiness at 6 
months. Lower average nightly CPAP use and presence of sleepiness at baseline are the primary 
determinants of persistent sleepiness in those using CPAP therapy, even among CPAP-adherent 
patients.  Specific strategies targeting these patients, including stressing the role of CPAP in 
decreasing sleepiness, frequent follow-up clinic visits to evaluate residual sleepiness and promote 
adherence,21,32 as well as thorough evaluation for other etiologies of sleepiness should be strongly 
considered. An appreciable number of OSA patients will continue to have sleepiness despite 
using CPAP. Other causes of sleepiness and other measures including addition of wake-
promoting medications should be considered in these patients. 
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Other term: Xihong Lin, PhD (2 y), Thomas H. Murray, PhD (1 y). 
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	Table	1:	Bivariate	correlation	between	clinical	and	PSG	variables	and	the	ESS	total	score	at	
baseline.	
Variable	 Pearson	Correlation	 P	
Age		 -0.07	 0.02	
BMI		 	0.10	 0.001	
AHI	 	0.08	 0.01	
Desaturation	Index	 	0.08	 0.01	
Sleep	Efficiency	 	0.09	 0.02	
HAMD	total	score	 	0.13	 <0.001	
	
PSG:	Polysomnographic	
ESS:	Epworth	Sleepiness	Scale		
BMI:	Body	Mass	Index	
AHI:	Apnea-Hypopnea	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
	 	
Table	2:	The	mean	ESS	total	score	and	proportion	of	sleepy	participants	in	various	medical	and	
psychiatric	disorders.	
	
Condition		
(n	with	
condition/		
n	without	
condition)	
	
Mean	ESS	
	
	
	
	
P	value	
%	of	participants	
with	ESS>	10	
	
P	value		
Condition	
present	
	
Condition	
absent	
	
Condition	
present	
	
Condition	
absent	
CVD	(399/706)	 10.2	±	4.4	 10.6	±	4.4	 0.26	 47.1	 50.3	 0.32	
Asthma	
(76/1022)	
10.6	±	4.7	 10.4	±	4.4	 0.81	 51.3	 48.9	 0.39	
GERD	(316/782)	 10.8	±	4.3	 10.3	±	4.4	 0.06	 52.2	 47.8	 0.20	
Nocturia	
(322/776)	
10.7	±	4.4	 10.3	±	4.4	 0.16	 52.8	 47.6	 0.13	
Chronic	Pain	
(173/925)	
11.1	±	4.5	 10.3	±	4.4	 0.03*	 53.2	 48.3	 0.14	
DM	(74/1024)	 10.6	±	4.7	 10.4	±	4.4	 0.41	 76.9	 68.5	 0.51	
Self-reported	
Depression	
(163/935)	
11.0	±	4.2	 10.3	±	4.4	 0.08*	 52.8	 48.4	 0.35	
Depression	
(HAMD		
Total	Score	≥8,	
204/894)	
11.4	±	4.7	 10.2	±	4.3	 <0.001*	 57.8	 47.0	 0.005*	
Anxiety	
(76/1021)	
11.0	±	4.0	 10.4	±	4.4	 0.23	 52.6	 48.8	 0.48	
Claustrophobia	
(88/1008)	
10.9	±	4.7	 10.4	±	4.4	 0.24	 51.1	 48.8	 0.32	
	
ESS:	Epworth	Sleepiness	Scale	
CVD:	Cardiovascular	Disease	
GERD:	Gastroesophageal	Reflux	Disease	
DM:	Diabetes	Mellitus	
HAMD:	Hamilton	Rating	Scale	for	Depression	
	 	
Table	3a:	Linear	regression	analysis	with	ESS	total	score	as	the	dependent	variable		
	
Variable	 Beta	 Std.	Error	 Standardized	
Coefficient	(Beta)	
t	 P	
Age	 -0.025	 0.011	 -0.068	 -2.211	 0.027*	
Gender	
(Female)	 0.530	 0.292	 0.057	 1.812	 0.070	
BMI	 0.021	 0.021	 0.033	 0.984	 0.325	
AHI	 0.012	 0.006	 0.066	 2.009	 0.045*	
HAMD		
Total	Score	≥8	 0.118	 0.033	 0.109	 3.556	 <0.001*	
Chronic	Pain	 0.609	 0.373	 0.050	 1.631	 0.103	
GERD	 0.364	 0.297	 0.037	 1.227	 0.220	
	
ESS:	Epworth	Sleepiness	Scale	
BMI:	Body	Mass	Index	
AHI:	Apnea-Hypopnea	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
	
	
	 	
Table	3b:	Odds	of	ESS	>	10	at	baseline	
	
Variable	 ESS>10	
(n=543)	
ESS<10	
(n=562)	
Wald	 Odds	Ratio	 P	
Age	(years)	 50.4	±	11.9	 52.7	±	12.4	 9.318	 0.984	 0.002*	
Gender	(Female)	,	n	(%)	
206	(37.9%)	 176	(31.3%)	 3.493	 1.290	 0.062	
BMI	(kg/m2)	 32.7	±	6.9	 31.7	±	7.3	 0.108	 1.003	 0.742	
Baseline	AHI	>30,	n	(%)	
312	(57.5%)	 299	(53.2%)	 2.974	 1.005	 0.085	
HAMD		
Total	Score	≥8,	n	(%)	 118	(21.9%)		 86	(15.4%)	 4.732	 1.423	 0.030*	
Chronic	Pain,	n	(%)	 92	(17.1%)	 81	(14.5%)	 0.624	 1.148	 0.429	
GERD,	n	(%)	
165	(30.6%)	 151	(27.0%)	 1.010	 1.149	 0.315	
	
ESS:	Epworth	Sleepiness	Scale	
BMI:	Body	Mass	Index	
AHI:	Apnea-Hypopnea	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
	
	
	
	
	
	
	
	
	 	
Table	3c:	Odds	of	objective	sleepiness	(MWT	<	20	minutes)	at	baseline	
	
	
Variable	 MWT	<	20	
(n=521)	
MWT	=	20	
(n=565)	
Odds	Ratio	 P	
Age	(years)	
49.6	±	12.6	 53.8	±	11.3	 0.972	 0.000*	
Gender	(Female)	,	n	(%)	
196	(34.7%)		 178	(34.2%)	 0.977	 0.868	
BMI	(kg/m2)	
33.1	±	7.4	 31.2	±	6.6	 1.018	 0.064	
Baseline	AHI	>30,	n	(%)	
354	(62.7%)		 249	(47.8%)	 1.858	 <0.001*	
HAMD		
Total	Score	≥8,	n	(%)	 123	(21.9%)		 79	(15.2%)	 1.500	 0.016*	
Chronic	Pain,	n	(%)	
91	(16.1%)	 81	(15.5%)	 1.081	 0.664	
GERD,	n	(%)	
161	(28.5%)	 149	(28.6%)	 0.921	 0.563	
	
	
MWT:	Maintenance	of	Wakefulness	Test	
BMI:	Body	Mass	Index	
AHI:	Apnea-Hypopnea	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
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Table	4a:	Linear	regression	analysis	with	ESS	total	score	at	6	months	as	the	dependent	variable		
 
Variable	 Beta	 Std.	Error	 Standardized	
Coefficient	(Beta)	
t	 P	
Age	 0.020	 0.015	 0.058	 1.328	 0.185	
Gender	
(Female)	 -0.548	 0.374	 -0.062	 -1.466	 0.143	
BMI	 -0.031	 0.025	 -0.055	 -1.210	 0.227	
HAMD	Total	
Score	 0.023	 0.040	 0.023	 0.566	 0.571	
Chronic	Pain	 0.766	 0.462	 0.069	 1.660	 0.098	
GERD	 0.045	 0.380	 0.005	 0.119	 0.906	
Baseline	ESS	 0.495	 0.039	 0.528	 12.679	 <0.001*	
AHI	Baseline	 -0.007	 0.008	 -0.038	 -0.841	 0.401	
AHI	at	6	
Months	 -0.025	 0.022	 -0.049	 -1.144	 0.253	
Mean	Hours	
of	CPAP	
Adherence	
-0.240	 0.067	 -0.151	 -3.579	 <0.001*	
	
ESS:	Epworth	Sleepiness	Scale	
BMI:	Body	Mass	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
AHI:	Apnea-Hypopnea	Index	
CPAP:	Continuous	Positive	Airway	Pressure	
	 	
Table	4b:	Odds	of	ESS	>10	at	6	months	
Variable	 ESS>10	(n=88)	 ESS<10	(n=306)	 Odds	Ratio	 P	
Age	(years)	 51.2	±	12.5	 53.0	±	12.0	 1.001	 0.920	
Gender	(Female)	,	n	(%)	
29	(33.0%)	 106	(34.6%)	 0.582	 0.049*	
BMI	(kg/m2)	 31.6	±	6.8	 32.2	±	7.3	 0.982	 0.356	
HAMD		
Total	Score	≥8,	n	(%)	 19	(21.6%)	 51	(16.7%)	 1.766	 0.059	
Chronic	Pain,	n	(%)	 23	(26.1%)	 45	(14.7%)	 2.289	 0.008*	
GERD,	n	(%)	 29	(33.0%)	 86	(28.1%)	 0.979	 0.939	
Baseline	ESS	>10,	n	(%)	
		65	(73.9%)	 127	(41.5%)	 5.143	 <0.001*	
Baseline	AHI	>30,	n	(%)	
48	(54.5%)	 171	(55.9%)	 1.106	 0.715	
AHI	>5	
at	6	Months,	n	(%)	 27	(30.7%)	 111	(36.3%)	 0.754	 0.291	
CPAP	Use	>4	Hours/Night,	
n	(%)	 48	(54.5%)	 217	(70.9%)	 0.425	 0.001*	
	
ESS:	Epworth	Sleepiness	Scale	
BMI:	Body	Mass	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
AHI:	Apnea-Hypopnea	Index	
CPAP:	Continuous	Positive	Airway	Pressure	
	
	
	
	 	
	
	
Table 4c: Odds of objective sleepiness (MSL-6m <20 minutes) at 6 months	
 
Variable	 MSL-6m	<	20	
(n=147)	
MSL-6m	=	20	
(n=233)	
Odds	Ratio	 P	
Age	(years)	 53.8	±	12.4 53.8	±	11.4 .994 .521 
Gender	(Female)	,	n	
(%)	 46	(31.3%) 84	(36.1%) .678 .109 
BMI	(kg/m2)	 32.2	±	6.7 31.9	±	7.2 1.004 .794 
HAMD		
Total	Score	≥8,	n	(%)	 30	(20.4%) 39	(16.7%) 1.168 .587 
Chronic	Pain,	n	(%)	
24	(16.3%) 43	(18.5%) .827 .524 
GERD,	n	(%)	 49	(33.3%) 65	(27.9%) 1.249 .364 
Baseline	MWT<20,	n	
(%)	 		156	(67.0%) 33	(22.4%) 6.711 .000* 
Baseline	AHI	>30,	n	(%)	
80	(54.4%) 128	(54.9%) .811 .398 
AHI	>5	
at	6	Months,	n	(%)	 51	(34.7%) 84	(36.1%) 1.020 .933 
CPAP	Use	>4	
Hours/Night,	n	(%)	 85	(57.8%) 169	(72.5%) .547 .008* 
	
MSL-6M:	Mean	Sleep	Latency-	6	Months	
BMI:	Body	Mass	Index	
HAMD:	Hamilton	Rating	Scale	for	Depression	
GERD:	Gastroesophageal	Reflux	Disease	
MWT:	Maintenance	of	Wakefulness	Test	
AHI:	Apnea-Hypopnea	Index	
CPAP:	Continuous	Positive	Airway	Pressure	
	 	
	Figure	1:	The	prevalence	of	sleepiness	in	all	participants	with	different	mean	daily	CPAP	use.
	
CPAP:	Continuous	Positive	Airway	Pressure		
ESS:	Epworth	Sleepiness	Scale	
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